Stoke Therapeutics Inc

NASDAQ STOK

Data sourced from iex and EODHD
Download Data

Stoke Therapeutics Inc Income Statement 2018 - 2024

This table shows the Income Statement for Stoke Therapeutics Inc going from 2018 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31
Revenue
M 4 3 3 -2 5 3 3 3 3 0 0 0 0 0 0 0 0 0 0 0 0 - - - 0
Cost of Revenue
M 1 1 1 1 1 1 - - - - - - - - - - - - - - 0 - - - 0
Gross Profit
M 3 2 2 -4 4 2 3 3 3 - - - - - - - - - - - 0 - - - 0
Operating Expenses
M 31 31 29 30 24 29 30 28 28 - - - - - - - - - - - 6 - - - 2
Selling, General, and Administrative Expenses (SG&A)
M 10 11 10 10 10 9 10 10 9 9 8 8 7 6 6 5 5 4 3 2 2 2 1 1 1
Research and Development (R&D) Expenses
M 22 21 20 21 20 21 20 18 18 16 14 14 10 9 8 8 7 7 7 6 4 3 2 2 1
Other Operating Expenses
M -1 -1 -1 -1 -5 -1 0 0 0 - - - - - - - - - - - 0 - - - 0
Costs and Expenses
M 30 30 29 30 29 29 - - - - - - - - - - - - - - 6 - - - 2
Operating Income
M -28 -30 -27 -33 -20 -27 -27 -25 -25 -25 -23 -22 -17 -15 -14 -13 -12 -11 -10 -8 -6 -5 -3 -3 -2
Interest Expense
M 2 3 3 3 2 1 1 1 0 0 0 0 - - - - - - - - 0 - - - 0
Non-operating Income/Expense
M 2 3 0 0 -2 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 - - 0
EBT
M -26 -27 -25 -31 -23 -26 -26 -25 -25 -24 -23 -22 -17 -15 -14 -13 -11 -10 -9 -8 -6 -4 -3 -3 -2
Income Tax Provision
M - 11 -3 -3 -4 -4 -2 -1 0 0 0 0 0 0 0 0 -1 -1 -1 -1 0 - - - 0
Income after Tax
M - -38 -21 -27 -18 -22 -24 -23 -24 -24 -23 -22 -17 -15 -13 -13 -10 -9 -7 -7 -6 - - - -2
Non-Controlling Interest
M - - 0 -6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Net Income
M - - -25 -25 -23 -26 -26 -25 -25 -24 -23 -22 -17 -15 -14 -13 -11 -10 -9 -8 -6 -4 -3 -3 -2
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 46,246,889.00 44,958,894.00 44,266,017.00 44,188,464.00 42,536,474.00 39,434,027.00 39,420,310.00 39,258,358.00 37,448,301.00 36,836,072.00 36,759,319.00 36,708,188.00 36,643,205.00 33,273,597.00 33,273,597.00 33,054,656.00 32,897,395.00 32,897,395.00 32,707,647.00 5,083,620.00 30,269,808.00 23,511,755.00 23,511,755.00 23,511,755.00 23,511,755.00
EBITDA
M -27 -28 -27 -33 -25 -27 -27 -25 -25 -25 -22 -22 -17 -14 -14 -13 -12 -11 -10 -8 -6 -4 -3 -3 -2
Depreciation and Amortization
M 1 1 1 1 -4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
EBIT
M -28 -30 -28 -34 -20 -28 -27 -26 -25 -25 -23 -22 -17 -15 -14 -13 -12 -11 -10 -8 -6 -5 -3 -3 -2
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - 0 - - - 0
Tax Rate (Effective)
% - -39.74 13.40 10.37 18.84 14.06 7.78 5.81 1.01 0.32 0.19 0.15 1.51 0.07 1.79 0.39 6.11 8.90 15.83 8.04 0.00 - - - 0.00
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit Margin
% 73.60 56.64 63.72 147.04 77.74 64.76 100.00 100.00 100.00 - - - - - - - - - - - - - - - -
Operating Income Margin
% -672.96 -1,055.89 -823.28 1,340.67 -396.78 -831.29 -934.53 -781.12 -826.50 - - - - - - - - - - - - - - - -
Net Income Margin
% - - -741.90 989.20 -437.60 -784.80 -898.83 -762.98 -821.63 - - - - - - - - - - - - - - - -
EBITDA Ratio
% -646.56 -1,012.53 -823.28 1,340.67 -479.23 -831.29 -921.17 -781.12 -818.27 - - - - - - - - - - - - - - - -
EBIT Ratio
% -672.96 -1,055.89 -842.53 1,365.30 -396.78 -849.92 -934.53 -790.47 -826.50 - - - - - - - - - - - - - - - -
EBT Ratio
% -625.57 -962.10 -741.90 1,235.55 -437.60 -784.80 -898.83 -762.98 -821.63 - - - - - - - - - - - - - - - -

StockViz Staff

September 19, 2024

Any question? Send us an email